# A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

> **NCT02756247** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Buparlisib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02756247
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2022-10-06
- **Final completion:** 2022-10-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02756247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02756247, "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02756247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*